Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Jun 1;183(6):2541-50.
doi: 10.1084/jem.183.6.2541.

CTLA-4 ligation blocks CD28-dependent T cell activation

Affiliations

CTLA-4 ligation blocks CD28-dependent T cell activation

T L Walunas et al. J Exp Med. .

Erratum in

  • J Exp Med 1996 Jul 1;184(1):301

Abstract

CTLA-4 is a CD28 homologue believed to be a negative regulator of T cell function. However, the mechanism of this downregulatory activity is not well understood. The present study was designed to examine the effect of CTLA-4 ligation on cytokine production, cell survival, and cell cycle progression. The results demonstrate that the primary effect of CTLA-4 ligation is not the induction of apoptosis. Instead, CTLA-4 signaling blocks IL-2 production, IL-2 receptor expression, and cell cycle progression of activated T cells. Moreover, the effect of CTLA-4 signaling was manifested after initial T cell activation. Inhibition of IL-2 receptor expression and cell cycle progression was more pronounced at late (72 h) time points after initial activation. The effects of anti-CTLA-4 mAbs were most apparent in the presence of optimal CD28-mediated costimulation consistent with the finding that CTLA-4 upregulation was CD28-dependent. Finally, the addition of exogenous IL-2 to the cultures restored IL-2 receptor expression and T cell proliferation. These results suggest that CTLA-4 signaling does not regulate cell survival or responsiveness to IL-2, but does inhibit CD28-dependent IL-2 production.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Exp Med. 1979 Sep 19;150(3):580-96 - PubMed
    1. J Immunol. 1995 Jun 1;154(11):5757-68 - PubMed
    1. J Immunol. 1981 Jan;126(1):317-21 - PubMed
    1. Immunity. 1995 Jul;3(1):87-98 - PubMed
    1. J Exp Med. 1995 Aug 1;182(2):459-65 - PubMed

Publication types

MeSH terms